Lipid solubility of vasodilatory vanilloid-type β-blockers on the functional and binding activities of β-adrenoceptor subtypes

General Pharmacology: The Vascular System

Volumn 34, Issue 5, 2000, Pages 321-328

  Wu, Bin Nan ^a   Shen, Kuo Pyng ^a   Lin, Rong Jyh ^a   Huang, Yeun Chih ^a   Chiang, Lien Chai ^a   Lo, Yi Ching ^a   Lin, Chiu Yin ^a   Chen, Ing Jim ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

3 Adrenoceptors; Interscapular brown adipose tissue; Lipid solubility; Spontaneous colonic motility; Vanilloid type blockers

Indexed keywords

4 (3 TERT BUTYLAMINO 2 HYDROXYPROPOXY) 2 BENZIMIDAZOLONE; ATENOLOL; BETA 1 ADRENERGIC RECEPTOR; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 3 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DEHYDROZINGERONOLOL; EUGENODILOL; EUGENOLOL; FERULIDILOL; FERULINOLOL; ISOEUGENOLOL; ISOPRENALINE; PROPRANOLOL; UNCLASSIFIED DRUG; VANIDILOL; VANILLOID TYPE BETA ADRENERGIC RECEPTOR BLOCKING AGENT; VANINOLOL; VASOMOLOL; ZINGERONOLOL;

ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING SITE; BROWN ADIPOSE TISSUE; CHRONOTROPISM; COLON MOTILITY; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; FEMALE; GUINEA PIG; HEART RIGHT ATRIUM; LIPID SOLUBILITY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; RECEPTOR BLOCKING; TRACHEA; VASODILATATION;

ADRENERGIC BETA-AGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; BINDING SITES; BINDING, COMPETITIVE; COLON; FEMALE; GUINEA PIGS; HEART ATRIA; HUMANS; ISOPROTERENOL; LIPID METABOLISM; MALE; MODELS, ANIMAL; RATS; RATS, WISTAR; RECEPTORS, ADRENERGIC; SOLUBILITY; TRACHEA; VASODILATOR AGENTS;

EID: 0034443514     PISSN: 03063623     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-3623(00)00076-8     Document Type: Article

References (37)

1. Arunlakshana, O., Schild, H.O., 1959. Some quantitative uses of drug antagonists. Br. J. Pharmacol. 14, 48-57.
2. Bianchetti, A., Manara, L., 1990. In vitro inhibition of intestinal motility by phenylethanolaminotetralines: evidence of atypical β-adrenoceptors in rat colon. Br. J. Pharmacol. 100, 831-839.
3. Boissel, J.P., Leizorovicz, A., Picolet, H., Peyrieux, J.C., 1990. Secondary prevention after high-risk acute myocardial infarction with low-dose acebutolol. Am. J. Cardiol. 66, 251-260.
4. Bradford, M.M., 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248-254.
5. Challis, R., Leighton, B., Wilson, S., Thurlby, P., Arch, J.R.S., 1988. An investigation of the β-adrenoceptor that mediates metabolic responses to the novel BRL 28410 in rat soleus muscle. Biochem. Pharmacol. 37, 947-950.
6. Chen, I.J., Yeh, J.L., Lo, Y.C., Sheu, S.H., Lin, Y.T., 1996. Capsinolol: the first β-adrenoceptor blocker with an associated calcitonin gene-related peptide releasing activity in the heart. Br. J. Pharmacol. 119, 7-14.
7. 2-agonist and calcium mobilization inhibition associated vasorelaxant activities. Drug Dev. Res. 40, 239-250.
8. 3 adrenergic receptor. Science 245, 118-121.
9. Frishman, W.H., 1991. Clinical perspective on celiprolol: cardioprotective potential. Am. Heart J. 21, 724-729.
10. Gengo, P.M., Huntoon, L., McHugh, W.B., 1987. Lipid-soluble and watersoluble β-blockers: comparison of the central nervous system depressant effect. Arch. Intern. Med. 147, 39-43.
11. 3 adrenergic receptor. Mol. Pharmacol. 40, 104-114.
12. Hellenbrecht, D., Müller, K.F., Grobecker, H., 1974. Prediction of the nonspecific cardiodepressant effects of β-adrenoceptor blocking agents in vitro and in vivo by means of the Hansch analysis. Eur. J. Pharmacol. 29, 223-235.
13. 2-agonist-associated vasorelaxant activities. J. Cardiovasc. Pharmacol. 34, 10-20.
14. 2-agonist activity. Drug Dev. Res. 47, 77-89.
15. Kardos, A., Long, V., Bryant, J., Singh, J., Sleight, P., Casadei, B., 1997. Lipophilic versus hydrophilic i blockers and the cardiac sympathovagal balance during stress and daily activity in patients after acute myocardial infarction. Heart 79, 153-160.
16. Kauman, A.J., 1989. Is there a third heart β-adrenoceptor? Trend Pharmacol. Sci. 10,316-320.
17. Lands, A.M., Arnold, A., McAuliff, J.P., Luduena, P.P., Brown, T.G., 1967. Differentiation of receptor systems activated by sympathomimetic amines. Nature 214, 597-598.
18. Lemmer, B., Neumann, G., 1987. Circadian phase dependency of the effects of different beta-receptor blocking drugs on motor activity of rats. Importance of drug lipophilicity. Arzneim-Forsch (Drug Res.) 37, 321-325.
19. 1-adrenoceptor antagonist. J. Cardiovasc. Pharmacol. 28, 149-157.
20. 1-adrenergic antagonist with trachea! and vascular smooth muscle relaxant properties. Jpn. J. Pharmacol. 80, 127-136.
21. Lowenthal, D.T., Saris, S.D., Packer, J., Haratz, A., Conry, K., 1984. Mechanisms of action and the clinical pharmacology of beta-adrcnergic blocking drugs. Am. J. Med. 77, 119-127.
22. 3-adrenoceptors. Br. J. Pharmacol. 120, 165-176.
23. Munson, P.J., Rodbard, D., 1980. LIGAND: a versatile computerized approach for the characterization of ligand-binding systems. Anal. Biochem. 107, 220-239.
24. Muzzin, P., Revelli, J.P., Kuhne, F., Gocayne, J.D., McCombie, W.R., Venter, J.C., Giacobino, J.P., Fraser, C.M., 1991. An adipose tissuespecific β-adrenergic receptor: molecular cloning and down-regulation in obesity. J. Biol. Chem. 266, 24053-24058.
25. 3H]CGP-12177. FEES Lett. 298, 162-164.
26. 3-adrenergic receptor: relationship with the atypical receptor of adipocytes. EMBO J. 10, 3721-3727.
27. 2 values on guinea-pig trachea and atria. Naunyn-Schmiedeberg's Arch. Pharmacol. 308, 183-190.
28. Parker, G.W., Michael, L.H., Hartely, C.J., Skinner, J.E., Entman, M.L., 1990. Central beta-adrenergic mechanisms may modulate ischémie ventricular fibrillation in pigs. Circ. Res. 66, 259-270.
29. Sheu, M.M., Wu, B.N., Ho, W.C., Hong, S.J., Chen, S.J., Lin, Y.T., Chen, I.J., 1997. Vanidilol: a vanilloid type vasorelaxant and ocular hypotensive beta-adrenoceptor blocker with partial beta-2-agonist activity. Pharmacology 54, 211-224.
30. 2 subtypes revealed by peptide maps. J. Biol. Chem. 258, 10689-10694.
31. Tyrer, P.J., 1980. Use of beta-blocking drugs in psychiatry and neurology. Drugs 20, 300-308.
32. Wikstrand, J., Kendall, M., 1992. The role of beta receptor blockade in preventing sudden death. Eur. Heart J. 13, 111-120.
33. Woods, P.B., Robinson, M.L., 1981. An investigation of the comparative liposolubilities of β-adrenoceptor blocking agents. J. Pharm. Pharmacol. 33, 172-173.
34. 1-adrenoceptor antagonists derived from vanillin. Biochem. Pharmacol. 48, 101-109.
35. Wu, B.N., Ho, W.C., Chiang, L.C., Chen, I.J., 1996. Zingeronolol: a newly developed β-adrcnergic blocking agent derived from zingerone, a pungent principle of ginger. Asia Pac. J. Pharmacol. 11, 5-12.
36. 2 agonist activity derived from ferulic acid, an active component of Ligusticum wallicliii FRANCH. J. Cardiovasc. Pharmacol. 31, 750-757.
37. Zaagsma, J., Nahorski, S.R., 1991. Is the adipocyte β-adrenoceptor a prototype for the recently cloned atypical "β-adrenoceptor"? Trends Pharmacol. Sci. 11, 3-7.